Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

The New Wegovy Pill Is Already Popular. Does That Make Novo Nordisk Stock a Buy for Q1?

Novo Nordisk A/S (NVO) kicked off 2026 with a major milestone: the U.S. launch of the Wegovy weight-loss pill. This marks the first oral GLP-1 therapy, which was approved by the Food and Drug Administration (FDA) in late December. And this wasn’t just another product rollout. It signaled a strategic shift in the way obesity treatment is delivered.

Where injectable GLP-1 drugs require in-office or self-administered shots, a daily pill dramatically lowers the barrier to treatment for millions of patients who prefer a familiar, convenient option. 

Fundamentals

See More
  • Market Capitalization, $K 984,418,880
  • Shares Outstanding, K 945,384
  • Annual Sales, $ 45,043 M
  • Annual Income, $ 10,590 M
  • EBIT $ 19,815 M
  • EBITDA $ 21,582 M
  • 60-Month Beta 0.35
  • Price/Sales 15.78
  • Price/Cash Flow 72.95
  • Price/Book 41.16

Options Overview Details

View History
  • Implied Volatility 39.45% (-1.41%)
  • Historical Volatility 29.15%
  • IV Percentile 71%
  • IV Rank 36.25%
  • IV High 64.53% on 04/07/25
  • IV Low 25.20% on 02/06/25
  • Expected Move (DTE 2) 18.78 (1.74%)
  • Put/Call Vol Ratio 0.85
  • Today's Volume 38,489
  • Volume Avg (30-Day) 38,073
  • Put/Call OI Ratio 1.02
  • Today's Open Interest 293,067
  • Open Int (30-Day) 369,875
  • Expected Range 1,059.43 to 1,096.99

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 7.50
  • Number of Estimates 7
  • High Estimate 8.72
  • Low Estimate 7.00
  • Prior Year 5.32
  • Growth Rate Est. (year over year) +40.98%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1,012.57 +6.59%
on 01/15/26
1,133.95 -4.82%
on 01/08/26
+7.84 (+0.73%)
since 12/19/25
3-Month
793.82 +35.96%
on 10/22/25
1,133.95 -4.82%
on 01/08/26
+279.71 (+34.98%)
since 10/21/25
52-Week
623.78 +73.02%
on 08/08/25
1,133.95 -4.82%
on 01/08/26
+336.93 (+45.39%)
since 01/21/25

Most Recent Stories

More News
The New Wegovy Pill Is Already Popular. Does That Make Novo Nordisk Stock a Buy for Q1?

Novo Nordisk entered 2026 with fresh momentum after the U.S. launch of its oral Wegovy pill. Is the stock a buy now?

NVO : 59.32 (-2.24%)
JPM : 302.04 (-0.23%)
LLY : 1,078.52 (+3.58%)
Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement

INDIANAPOLIS , Jan. 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2025 financial results on February 4, 2026. Lilly will also conduct a conference...

LLY : 1,078.52 (+3.58%)
3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026

These three biotech stocks combine scale, late-stage pipelines, and analyst confidence, giving investors compelling upside potential in 2026

VKTX : 33.39 (-0.39%)
LLY : 1,078.52 (+3.58%)
BIIB : 172.62 (+4.38%)
Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer

INDIANAPOLIS , Jan. 20, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sofetabart...

LLY : 1,078.52 (+3.58%)
Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All

As weight loss drugs move from injections to pills, this thematic ETF provides broad exposure for investors looking to profit from the industry’s next leg up.

VKTX : 33.39 (-0.39%)
AZN : 90.54 (+0.67%)
OZEM : 36.09 (+1.04%)
NVO : 59.32 (-2.24%)
LLY : 1,078.52 (+3.58%)
REGN : 749.33 (+2.12%)
AMGN : 343.60 (+3.81%)
PFE : 25.89 (+1.45%)
Stocks Boosted by Chip Demand Optimism

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed up +0.26%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.60%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.32%. March E-mini...

MSTR : 163.81 (+2.23%)
BLK : 1,127.85 (+1.60%)
AMAT : 325.17 (+2.18%)
MPC : 177.48 (+1.49%)
SNDK : 501.29 (+10.63%)
ADI : 304.97 (+3.15%)
MLTX : 16.71 (+2.33%)
$IUXX : 25,326.58 (+1.36%)
COIN : 226.93 (-0.35%)
ASML : 1,360.09 (+2.57%)
ZNH26 : 111-215 (+0.22%)
OXY : 43.51 (+3.01%)
Why Eli Lilly (LLY) Stock Is Down Today

Why Eli Lilly (LLY) Stock Is Down Today

LLY : 1,078.52 (+3.58%)
Stocks Supported by Strength in Chip Makers and US Economic News

The S&P 500 Index ($SPX ) (SPY ) today is up +0.49%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.75%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.07%. March E-mini S&P futures (ESH26...

BLK : 1,127.85 (+1.60%)
MSTR : 163.81 (+2.23%)
AMAT : 325.17 (+2.18%)
MPC : 177.48 (+1.49%)
SNDK : 501.29 (+10.63%)
ADI : 304.97 (+3.15%)
MLTX : 16.71 (+2.33%)
$IUXX : 25,326.58 (+1.36%)
ASML : 1,360.09 (+2.57%)
ZNH26 : 111-215 (+0.22%)
OXY : 43.51 (+3.01%)
ESH26 : 6,915.00 (+1.25%)
The $69B Precision Pivot: Why Biomarker Platforms are Igniting a New Oncology Gold Rush

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The genomics in cancer care market is on a massive tear, projected to hit $69.16 billion by 2032 as doctors...

ONCY : 1.1700 (+18.11%)
BCT.TO : 5.83 (-3.80%)
ACRV : 2.0900 (+6.63%)
LLY : 1,078.52 (+3.58%)
BCTX : 4.21 (-3.66%)
GLSI : 22.30 (+4.74%)
CATX : 2.55 (+4.94%)
A Fresh IPO That Long-Term Investors Shouldn’t Ignore

Aktis Oncology, which recently had its IPO, has gained substantial backing from Big Pharma mainstay Eli Lilly. Investors should take note of the biotech firm.

SFD : 23.11 (-1.11%)
CRWV : 94.05 (-1.23%)
AKTS : 20.40 (+8.68%)
LLY : 1,078.52 (+3.58%)
MDLN : 43.30 (-1.93%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 1,082.66
2nd Resistance Point 1,064.26
1st Resistance Point 1,052.77
Last Price 1,078.52
1st Support Level 1,022.88
2nd Support Level 1,004.48
3rd Support Level 992.99

See More

52-Week High 1,133.95
Last Price 1,078.52
Fibonacci 61.8% 939.07
Fibonacci 50% 878.86
Fibonacci 38.2% 818.66
52-Week Low 623.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar